Skip to content

CROI: Tenofovir and kidney toxicity - low rates seen, but some groups may be more vulnerable

CROI: CD4-guided treatment interruptions unsafe, SMART study concludes

CROI: Antiretroviral therapy reduces the high incidence of TB in South African children with HIV

CROI: Abacavir may be safer than nevirapine in Africans, DART sub-study suggests

CROI: Atazanavir/ritonavir joins other boosted PIs as potential single-class maintenance regimen

CROI: HIV subtype D causes disease more rapidly than HIV-1 subtype A in Uganda

CROI: Rapid scale-up of HIV treatment in Zambia

CROI: Valaciclovir reduces HIV genital shedding in HIV-positive women

CROI: 70% still on first regimen after three years in Khayelitsha, but lactic acidosis a major challenge